Omnicell Acquires ReCept

Biogen Acquires Reata Pharmaceuticals

July 28, 2023

Biotechnology

Biogen Inc. agreed to acquire Reata Pharmaceuticals, Inc. for $172.50 per share in cash, representing an enterprise value of approximately $7.3 billion. The acquisition adds Reata's FDA-approved SKYCLARYS (omaveloxolone) for Friedreich's ataxia to Biogen's rare disease portfolio and is expected to be significantly accretive to Biogen's Non-GAAP diluted EPS beginning in 2025; the transaction was anticipated to close in Q4 2023.

Omnicell Acquires MarkeTouch Media

December 31, 2021

Healthcare Services

Omnicell, Inc. acquired pharmacy software and patient engagement provider MarkeTouch Media, LLC for $82 million in cash. The deal expands Omnicell’s EnlivenHealth footprint in the retail and specialty pharmacy markets and adds MarkeTouch’s mobile/web-based SaaS patient engagement capabilities to accelerate Omnicell’s SaaS roadmap.

Recipharm AB Acquires Vibalogics from Ampersand Capital Partners

February 18, 2022

Biotechnology

Recipharm AB, a global CDMO based in Sweden, has agreed to acquire Vibalogics, a virotherapy-focused CDMO and Ampersand Capital Partners portfolio company. The deal expands Recipharm's capabilities into viral vaccines, viral vectors and oncolytic virus manufacturing while Vibalogics will continue operating from its Boxborough, MA and Cuxhaven, Germany facilities.

Recro Pharma Acquires IRISYS (San Diego)

August 13, 2021

Pharmaceuticals

Recro Pharma (NASDAQ: REPH) acquired San Diego–based CDMO IRISYS for approximately $49.85 million in cash, stock and a seller promissory note, transforming Recro into a bi‑coastal, full‑service CDMO. The acquisition expands Recro's capabilities (including aseptic fill/finish and lyophilization), diversifies its client base and adds near‑term revenue and backlog.

Change Healthcare Acquires eRx Network

May 4, 2020

Healthcare Services

Change Healthcare has exercised its option and acquired 100% of eRx Network for $212.9 million plus cash, with eRx generating approximately $67 million of revenue for the twelve months ended February 29, 2020. The acquisition expands Change Healthcare's pharmacy-focused technology and data capabilities, enabling tighter integration of pharmacy interactions with claims, billing and payment data to drive improved outcomes and new product opportunities.

Prescient Healthcare Group Acquires Uptake

January 9, 2026

Healthcare Services

Prescient Healthcare Group has acquired Uptake (Uptake Strategies Ltd), a global healthcare consultancy, to strengthen Prescient’s commercial practice and expand capabilities for pharmaceutical and biotech clients. The deal is supported by Prescient’s existing investor Bridgepoint Development Capital; Uptake’s CEO Stephanie Hall will join Prescient’s board and lead the combined Commercial Practice during integration.